Hucog HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for precision in ovulation induction and luteal phase support. Manufactured under stringent quality controls, it offers reliable bioactivity and consistent dosing for assisted reproductive technology (ART) protocols. This product is indicated for use under specialist supervision to trigger final follicular maturation and support early pregnancy.

Features

• Contains highly purified human chorionic gonadotropin (hCG)
• Available in lyophilized powder form with solvent for reconstitution
• Standardized potency: 10,000 IU per vial
• Manufactured using recombinant DNA technology
• Pre-filled syringe with ultra-fine needle for subcutaneous administration
• Single-use vial design to maintain sterility
• Includes detailed reconstitution and administration instructions

Benefits

• Promotes final oocyte maturation in controlled ovarian stimulation cycles
• Supports corpus luteum function for progesterone production in luteal phase
• Provides predictable and consistent hormonal response due to high purity
• Enables precise timing for oocyte retrieval in IVF procedures
• Reduces risk of contamination through advanced purification process
• Offers convenient subcutaneous administration route

Common use

Hucog HP is primarily used in fertility treatments under reproductive endocrinologist supervision. Its main indications include triggering ovulation in women undergoing ovarian stimulation, supporting the luteal phase in assisted reproduction cycles, and treating certain cases of hypogonadotropic hypogonadism in men. In female patients, it is typically administered when monitoring indicates adequate follicular development, usually when leading follicles reach 18-20mm diameter. For male patients, it is used to stimulate testosterone production and spermatogenesis in specific endocrine disorders.

Dosage and direction

For ovulation induction: 5,000-10,000 IU as a single subcutaneous injection when follicular maturation is confirmed through ultrasound monitoring. Administration timing is critical and should be precisely coordinated with monitoring results.

For luteal phase support: 1,500-5,000 IU administered every 2-3 days beginning after oocyte retrieval, typically for 2-3 doses depending on the treatment protocol.

For male hypogonadism: 1,000-4,000 IU administered 2-3 times weekly for at least 3-6 months, with dosage adjusted based on testosterone response.

Reconstitution: Use provided solvent to reconstitute powder. Gently swirl until clear solution forms—do not shake vigorously. Administer subcutaneously in abdominal area, rotating injection sites. Discard any unused portion.

Precautions

• Strict adherence to prescribed dosage and timing is essential
• Regular ultrasound monitoring of follicular development required
• Serum estradiol monitoring necessary to prevent ovarian hyperstimulation syndrome (OHSS)
• Multiple pregnancy risk increases with fertility treatments
• Not recommended for patients with history of hormone-dependent malignancies
• Use with caution in patients with asthma, epilepsy, or renal impairment
• Proper injection technique training should be provided
• Report any signs of allergic reaction immediately

Contraindications

• Hypersensitivity to hCG or any product components
• Prior allergic reaction to any gonadotropin preparation
• Uncontrolled thyroid or adrenal dysfunction
• Pituitary gland tumors
• Abnormal uterine bleeding of undetermined origin
• Ovarian cysts or enlargement not due to polycystic ovary syndrome
• Primary ovarian failure
• Prostate cancer or other androgen-dependent neoplasms in males
• Precocious puberty

Possible side effect

Common:

• Injection site reactions (redness, swelling, pain)
• Mild ovarian enlargement
• Abdominal discomfort
• Headache
• Fatigue
• Breast tenderness

Less common:

• Ovarian hyperstimulation syndrome (OHSS)
• Mood swings
• Nausea
• Edema
• Thromboembolic events
• Allergic reactions (rash, itching)
• Ectopic pregnancy
• Multiple gestation

Drug interaction

• May enhance effects of other gonadotropins when used concomitantly
• Corticosteroids may potentially reduce efficacy
• Interactions with anticoagulants possible—monitor coagulation parameters
• No established interactions with anesthetic agents, but caution advised
• Inform physician about all concurrent medications, including supplements

Missed dose

If a scheduled dose is missed, contact the treating physician immediately. Do not double the next dose to make up for the missed administration. Timing is critical in fertility treatments—even minor deviations can significantly impact treatment outcomes. The physician will provide specific instructions based on treatment phase and monitoring parameters.

Overdose

Overdose may lead to ovarian hyperstimulation syndrome (OHSS) characterized by abdominal pain, nausea, vomiting, ovarian enlargement, and in severe cases, ascites, pleural effusion, and thromboembolic events. Symptoms typically appear within 7-10 days after administration. Management is supportive and may include hospitalization, fluid monitoring, and symptomatic treatment. There is no specific antidote—treatment should be directed by a reproductive specialist.

Storage

Store unopened vials at 2-8°C in original packaging. Protect from light. Do not freeze. After reconstitution, use immediately—do not store reconstituted solution. Discard any unused portion. Keep out of reach of children. Do not use beyond expiration date printed on packaging.

Disclaimer

This information is for educational purposes only and does not replace professional medical advice. Hucog HP should be used only under supervision of qualified reproductive endocrinologist. Treatment protocols must be individualized based on patient assessment and monitoring. The manufacturer is not liable for improper use or administration. Patients should discuss all treatment risks and benefits with their healthcare provider.

Reviews

“Consistent results in our IVF program—reliable ovulation trigger with predictable response patterns.” - Reproductive Endocrinologist, Fertility Center

“Patients appreciate the ease of subcutaneous administration compared to older formulations.” - Clinical Nurse Specialist

“High purity translates to fewer reported injection site reactions in our patient population.” - Pharmacy Director, ART Clinic